GHRH analog
Tesamorelin
A growth hormone-releasing factor analog with product-specific clinical evidence and materially different regulatory status by country.
Why it is discussed
A narrow approved use in HIV-associated lipodystrophy
Tesamorelin is discussed for growth-hormone-axis and abdominal-fat claims. In the US, its authorized use is specifically reduction of excess abdominal fat in adults with HIV and lipodystrophy; the label explicitly says it is not a general weight-management medicine.
What it is
A modified version of growth-hormone-releasing hormone.
Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone, also called growth-hormone-releasing factor. It contains the hormone's 44-amino-acid sequence with a modification at one end. It acts upstream of growth hormone rather than supplying growth hormone itself.
How it works
Pituitary signaling followed by growth hormone and IGF-1.
Tesamorelin activates GHRH receptors on growth-hormone-producing cells in the pituitary gland. This stimulates release of the body's own growth hormone, which also increases IGF-1 production in the liver and other tissues. These signals affect metabolism and tissue growth.
A human mechanistic study measured increased endogenous growth-hormone pulse activity. This supports its action on the hormone pathway, but a change in a hormone measurement is not by itself evidence of a desirable outcome for every person.
Growth hormone can influence fat metabolism, but this does not make tesamorelin a general weight-loss or anti-aging treatment. Benefits and risks established for a specific authorized product and population do not transfer to a differently manufactured preparation.
Scientific / evidence sources
Evidence at a glance
What is established—and what is not.
Product-specific clinical trials and a narrow US approval
Controlled clinical evidence supports a specific FDA-approved tesamorelin product for reduction of excess abdominal fat in adults with HIV and lipodystrophy.
That evidence does not make tesamorelin a general weight-management product or validate generic research vials and off-label claims.
Regulatory status
Canada and the United States are checked separately.
Health Canada records show prior EGRIFTA DINs, but the reviewed 1 mg and 2 mg records are canceled. Verify the live database before treating any product as currently marketed.
EGRIFTA SV is FDA approved for a specific HIV-lipodystrophy indication. Approval and reconstitution instructions apply to that labeled product, not generic research vials.
Regulatory status describes product authorization and relevant regulatory context. It is not a complete legal opinion about possession, importation, prescribing, sale, or professional practice.
If you are reviewing a product report
The molecule profile and the testing report answer different questions.
This page summarizes evidence and regulatory context. A laboratory report may address identity, purity, or quantity for one submitted sample; it does not transfer clinical evidence or product authorization.